Founded in 2016, and derived from frontline clinical experience, BiVictriX is a rapidly emerging biotechnology company applying a novel approach to develop safer, more effective cancer therapies We have developed our Bi-Cygni® therapeutics, which are uniquely selective for particular cancer types, to enable higher dosing and more aggressive cancer eradication without causing harmful side-effects We apply state of the art techniques to identify combinations of cancer-specific targets for both solid and liquid tumors